vs
CSW INDUSTRIALS, INC.（CSW）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
CSW INDUSTRIALS, INC.的季度营收约是VERACYTE, INC.的1.7倍（$233.0M vs $139.1M），VERACYTE, INC.净利率更高（20.6% vs 4.4%，领先16.2%），VERACYTE, INC.同比增速更快（21.5% vs 20.3%），过去两年VERACYTE, INC.的营收复合增速更高（10.2% vs 5.1%）
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
CSW vs VCYT — 直观对比
营收规模更大
CSW
是对方的1.7倍
$139.1M
营收增速更快
VCYT
高出1.2%
20.3%
净利率更高
VCYT
高出16.2%
4.4%
两年增速更快
VCYT
近两年复合增速
5.1%
损益表 — Q3 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $233.0M | $139.1M |
| 净利润 | $10.3M | $28.7M |
| 毛利率 | 39.7% | 72.7% |
| 营业利润率 | 7.4% | 16.3% |
| 净利率 | 4.4% | 20.6% |
| 营收同比 | 20.3% | 21.5% |
| 净利润同比 | -61.9% | — |
| 每股收益（稀释后） | $0.62 | $0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSWVCYT
| Q1 26 | — | $139.1M | ||
| Q4 25 | $233.0M | $140.6M | ||
| Q3 25 | $277.0M | $131.9M | ||
| Q2 25 | $263.6M | $130.2M | ||
| Q1 25 | $230.5M | $114.5M | ||
| Q4 24 | $193.6M | $118.6M | ||
| Q3 24 | $227.9M | $115.9M | ||
| Q2 24 | $226.2M | $114.4M |
净利润CSWVCYT
| Q1 26 | — | $28.7M | ||
| Q4 25 | $10.3M | $41.1M | ||
| Q3 25 | $40.7M | $19.1M | ||
| Q2 25 | $40.9M | $-980.0K | ||
| Q1 25 | $35.1M | $7.0M | ||
| Q4 24 | $26.9M | $5.1M | ||
| Q3 24 | $36.1M | $15.2M | ||
| Q2 24 | $38.6M | $5.7M |
毛利率CSWVCYT
| Q1 26 | — | 72.7% | ||
| Q4 25 | 39.7% | 72.5% | ||
| Q3 25 | 43.0% | 69.2% | ||
| Q2 25 | 43.8% | 69.0% | ||
| Q1 25 | 44.2% | 69.5% | ||
| Q4 24 | 41.4% | 66.4% | ||
| Q3 24 | 45.6% | 68.2% | ||
| Q2 24 | 47.5% | 68.1% |
营业利润率CSWVCYT
| Q1 26 | — | 16.3% | ||
| Q4 25 | 7.4% | 26.4% | ||
| Q3 25 | 20.5% | 17.4% | ||
| Q2 25 | 20.8% | -4.0% | ||
| Q1 25 | 19.5% | 2.5% | ||
| Q4 24 | 15.3% | 3.5% | ||
| Q3 24 | 22.6% | 10.4% | ||
| Q2 24 | 24.3% | 4.0% |
净利率CSWVCYT
| Q1 26 | — | 20.6% | ||
| Q4 25 | 4.4% | 29.3% | ||
| Q3 25 | 14.7% | 14.5% | ||
| Q2 25 | 15.5% | -0.8% | ||
| Q1 25 | 15.2% | 6.2% | ||
| Q4 24 | 13.9% | 4.3% | ||
| Q3 24 | 15.8% | 13.1% | ||
| Q2 24 | 17.1% | 5.0% |
每股收益（稀释后）CSWVCYT
| Q1 26 | — | $0.35 | ||
| Q4 25 | $0.62 | $0.50 | ||
| Q3 25 | $2.41 | $0.24 | ||
| Q2 25 | $2.43 | $-0.01 | ||
| Q1 25 | $2.05 | $0.09 | ||
| Q4 24 | $1.60 | $0.07 | ||
| Q3 24 | $2.26 | $0.19 | ||
| Q2 24 | $2.47 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $40.2M | $439.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.1B | $1.3B |
| 总资产 | $2.3B | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CSWVCYT
| Q1 26 | — | $439.1M | ||
| Q4 25 | $40.2M | $362.6M | ||
| Q3 25 | $31.5M | $315.6M | ||
| Q2 25 | $38.0M | $219.5M | ||
| Q1 25 | $225.8M | $186.1M | ||
| Q4 24 | $213.8M | $239.1M | ||
| Q3 24 | $273.2M | $274.1M | ||
| Q2 24 | $18.9M | $235.9M |
总债务CSWVCYT
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $800.1M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益CSWVCYT
| Q1 26 | — | $1.3B | ||
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $1.1B | $1.2B | ||
| Q1 25 | $1.1B | $1.2B | ||
| Q4 24 | $1.0B | $1.2B | ||
| Q3 24 | $1.0B | $1.2B | ||
| Q2 24 | $650.2M | $1.1B |
总资产CSWVCYT
| Q1 26 | — | $1.4B | ||
| Q4 25 | $2.3B | $1.4B | ||
| Q3 25 | $1.5B | $1.4B | ||
| Q2 25 | $1.5B | $1.3B | ||
| Q1 25 | $1.4B | $1.3B | ||
| Q4 24 | $1.4B | $1.3B | ||
| Q3 24 | $1.4B | $1.3B | ||
| Q2 24 | $1.1B | $1.2B |
负债/权益比CSWVCYT
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.9M | $35.2M |
| 自由现金流经营现金流 - 资本支出 | $22.7M | — |
| 自由现金流率自由现金流/营收 | 9.8% | — |
| 资本支出强度资本支出/营收 | 2.6% | — |
| 现金转化率经营现金流/净利润 | 2.81× | 1.23× |
| 过去12个月自由现金流最近4个季度 | $162.0M | — |
8季度趋势，按日历期对齐
经营现金流CSWVCYT
| Q1 26 | — | $35.2M | ||
| Q4 25 | $28.9M | $52.6M | ||
| Q3 25 | $61.8M | $44.8M | ||
| Q2 25 | $60.6M | $33.6M | ||
| Q1 25 | $27.3M | $5.4M | ||
| Q4 24 | $11.6M | $24.5M | ||
| Q3 24 | $66.8M | $30.0M | ||
| Q2 24 | $62.7M | $29.6M |
自由现金流CSWVCYT
| Q1 26 | — | — | ||
| Q4 25 | $22.7M | $48.8M | ||
| Q3 25 | $58.7M | $42.0M | ||
| Q2 25 | $57.7M | $32.3M | ||
| Q1 25 | $22.8M | $3.5M | ||
| Q4 24 | $8.5M | $20.4M | ||
| Q3 24 | $61.3M | $27.7M | ||
| Q2 24 | $59.6M | $26.8M |
自由现金流率CSWVCYT
| Q1 26 | — | — | ||
| Q4 25 | 9.8% | 34.7% | ||
| Q3 25 | 21.2% | 31.8% | ||
| Q2 25 | 21.9% | 24.8% | ||
| Q1 25 | 9.9% | 3.1% | ||
| Q4 24 | 4.4% | 17.2% | ||
| Q3 24 | 26.9% | 23.9% | ||
| Q2 24 | 26.3% | 23.4% |
资本支出强度CSWVCYT
| Q1 26 | — | — | ||
| Q4 25 | 2.6% | 2.7% | ||
| Q3 25 | 1.1% | 2.1% | ||
| Q2 25 | 1.1% | 1.0% | ||
| Q1 25 | 2.0% | 1.6% | ||
| Q4 24 | 1.6% | 3.5% | ||
| Q3 24 | 2.4% | 1.9% | ||
| Q2 24 | 1.4% | 2.4% |
现金转化率CSWVCYT
| Q1 26 | — | 1.23× | ||
| Q4 25 | 2.81× | 1.28× | ||
| Q3 25 | 1.52× | 2.34× | ||
| Q2 25 | 1.48× | — | ||
| Q1 25 | 0.78× | 0.76× | ||
| Q4 24 | 0.43× | 4.80× | ||
| Q3 24 | 1.85× | 1.98× | ||
| Q2 24 | 1.62× | 5.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSW
| Contractor Solutions Segment | $166.3M | 71% |
| Specialized Reliability Solutions Segment | $38.2M | 16% |
| Engineered Building Solutions Segment | $28.5M | 12% |
VCYT
| Testing revenue | $135.1M | 97% |
| Product revenue | $3.7M | 3% |
| Biopharmaceutical and other revenue | $301.0K | 0% |
